Febuxostat: A new agent for lowering serum urate

Drugs of Today

Volumn 45, Issue 4, 2009, Pages 247-260

  Keenan, Robert T ^a   Pillinger, Michael H ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTACID AGENT; AZATHIOPRINE; BEZAFIBRATE; CAPTOPRIL; COLCHICINE; DIGOXIN; FEBUXOSTAT; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; NAPROXEN; NITRENDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; URIC ACID; VERAPAMIL; WARFARIN; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMMON COLD; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSGEUSIA; EPIGASTRIC DISCOMFORT; FATIGUE; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL SYMPTOM; GOUT; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; JOINT STIFFNESS; JOINT SWELLING; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MUSCLE STIFFNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OBESITY; PERIPHERAL EDEMA; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH DISCOMFORT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; VOMITING;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; KIDNEY DISEASES; LIVER DISEASES; THIAZOLES;

EID: 68249124507     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.045.004.1354217     Document Type: Review

References (69)

1. Nuki, G., Simkin, P.A. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006, 8(Suppl. 1): S1. (Pubitemid 43919292)
2. Winnard, D., Kake, T., Gow, P. et al. Debunking the myths to provide 21st century management of gout. N Z Med J 2008, 121(1274): 79-85. (Pubitemid 351850323)
3. Hakoda, M. [Epidemiology of hyperuricemia and gout in Japan]. Nippon Rinsho 2008, 66(4): 647-652
4. Lawrence, R.C., Felson, D.T., Helmick, C.G. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58(1): 26-35.
5. Shoji, A., Yamanaka, H., Kamatani, N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51(3): 321-325 (Pubitemid 38725128)
6. Hall, A.P., Barry, P.E., Dawber, T.R., McNamara, P.M. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967, 42(1): 27-37.
7. Kramer, H.M., Curhan, G. The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002, 40(1): 37-42.
8. Wallace, K.L., Riedel, A.A., Joseph-Ridge, N., Wortmann, R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004, 31(8): 1582-1587 (Pubitemid 39006641)
9. Choi, H.K., Ford, E.S., Li, C., Curhan, G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007, 57(1): 109-115 (Pubitemid 46256732)
10. Choi, H.K., Ford, E.S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007, 120(5): 442-447 (Pubitemid 46656248)
11. Ter Maaten, J.C., Voorburg, A., Heine, R.J., Ter Wee, P.M., Donker, A.J., Gans, R.O. Renal handling of urate and sodium during acute physiological hypermsulinaemia in healthy subjects. Clin Sci (Lond) 1997, 92(1): 51-58 (Pubitemid 27033010)
12. Facchini, F., Chen, Y.D., Hollenbeck, C.B., Reaven, G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266(21): 3008-3011
13. Muscelli, E., Natali, A., Bianchi, S. et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996, 9(8): 746-752 (Pubitemid 26271219)
14. Sundstrom, J., Sullivan, L., D'Agostino, R.B., Levy, D., Kannel, W.B., Vasan, R.S. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005, 45(1): 28-33. (Pubitemid 40066409)
15. Strazzullo, P., Puig, J.G. Uric acid and oxidative stress: Relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 2007, 17(6): 409-414
16. Gur, M., Yilmaz, R., Demirbag, R. et al. Relationship between myocardial performance index and aortic distensibihty in patients with essential hypertension. Int J Clin Pract 2008, 62(1): 138-142 (Pubitemid 350293999)
17. Kanbay, M., Ozkara, A., Selcoki, Y. et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007, 39(4): 1227-1233 (Pubitemid 350193621)
18. Krishnan, E., Kwoh, C.K., Schumacher, H.R., Kuller, L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007, 49(2): 298-303. (Pubitemid 46143005)
19. Emmerson, B.T. The management of gout. N Engl J Med 1996, 334(7): 445-451
20. Li-Yu, J, Clayburne, G., Sieck, M. et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001, 28(3): 577-580
21. Horiuchi, H., Ota, M., Kaneko, H., Kasahara, Y., Ohta, T., Komoriya, K. Nephrotoxic effects of allopurinol in dinitrofluorobenzene-sensitized mice: comparative studies on TEI-6720. Res Commun Mol Pathol Pharmacol 1999, 104(3): 293-305. (Pubitemid 30158751)
22. Markel, A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J 2005, 7(10): 656-660
23. Pereira, S., Almeida, J., Silva, A.O., Quintas, M., Candeias, O., Freitas, F. [Fatal liver necrosis due to allopurinol]. Acta Med Port 1998, 11(12): 1141-1144
24. Fam, A.G. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 2001, 3(1): 29-35.
25. Takano, Y., Hase-Aoki, K., Horiuchi, H. et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005, 76(16): 1835-47. (Pubitemid 40215224)
26. Becker, M.A., Schumacher, H.R., Jr., Wortmann, R.L. et al. Febuxostat, a novel nonpuhne selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52(3): 916-923
27. Wortmann, R.L., Ridolfo, A.S., Lightfoot, R.W., Jr., Fox, I.H. Antihyperuricemic properties of amflutizole in gout. J Rheumatol 1985, 12(3): 540-543
28. Bindoli, A., Valente, M., Cavallini, L. Inhibitory action of quercetin on xanthine oxidase and xanthine dehydrogenase activity. Pharmacol Res Commun 1985, 17(9): 831-839 (Pubitemid 15238804)
29. Hall, I.H., Scoville, J.P., Reynolds, D.J., Simlot, R., Duncan, P. Substituted cyclic imides as potential anti-gout agents. Life Sci 1990, 46(26): 1923-1927 (Pubitemid 20205064)
30. Osada, Y., Tsuchimoto, M., Fukushima, H., Takahashi, K., Kondo, S., Hasegawa, M., Komoriya, K. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993, 241(2-3): 183-188 (Pubitemid 23272878)
31. Fukunari, A., Okamoto, K., Nishino, T. et al. Y-700 [1-[3-Cyano-4-(2,2- dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther 2004, 311(2): 519-28. (Pubitemid 39391536)
32. Sato, S., Tatsumi, K., Nishino, T. A novel xanthine dehydrogenase inhibitor (BOF-4272). Adv Exp Med Biol 1991, 309A: 135-138
33. Komoriya, K., Osada, Y., Hasegawa, M., Horiuchi, H., Kondo, S., Couch, R.C., Griffin, T.B. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol 1993, 250(3): 455-460 (Pubitemid 24010981)
34. Bruce, S,P. Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006, 40(12): 2187-2194 (Pubitemid 44954438)
35. Mayer, M.D., Khosravan, R., Vernillet, L., Wu, J.T., Joseph-Ridge, N., Mulford, D.J. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005, 12(1): 22-34. (Pubitemid 40516043)
36. Becker, M.A., Kisicki, J., Khosravan, R. et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004, 23(8-9): 1111-1116 (Pubitemid 39625877)
37. Khosravan, R., Grabowski, B.A., Wu, J.T., Joseph-Ridge, N., Vernillet, L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 2006, 45(8): 821-841 (Pubitemid 44192308)
38. Khosravan, R., Wu, J.T., Joseph-Ridge, N., Vernillet, L. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 2006, 46(8): 855-866 (Pubitemid 44050822)
39. Khosravan, R., Grabowski, B.A., Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006, 46(1): 88-102. (Pubitemid 43021717)
40. Mikuls, T.R., Farrar, J.T., Bilker, W.B., Fernandes, S., Schumacher, H.R., Jr., Saag, K.G. Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005, 64(2): 267-272
41. Khosravan, R., Kukulka, M.J., Wu, J.T., Joseph-Ridge, N., Vernillet, L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008, 48(9): 1014-1024
42. Khosravan, R., Grabowski, B., Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol 2008, 65(3): 355-363 (Pubitemid 351316909)
43. Becker, M., MacDonald, P.A., Lloyd, E.J., Lademacher, C., Joseph-Ridge N. Urate-lowering pharmacotherapy with febuxostat or allopurinol in Black-American subjects with gout. Ann Rheum Dis 2007, 66(Suppl II): 231.
44. Schumacher, H.R.,Jr., Becker, M.A., MacDonald, P.A., Lloyd, E.J, Lademacher, C., Joseph-Ridge, N. Febuxostat versus allopurinol in the treatment of gout in subjects 65 years of age or older. Ann Rheum Dis 2007, 66(Suppl II): 234.
45. Grabowski, B.A., Khosravan, R., Wu, J.T., Lademacher, C., Vernillet, L. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthritis Rheum 2005, 52(Suppl.): S103-S104.
46. Khosravan, R., Mayer, M.D., Wu, J.T., Joseph-Ridge, N., Vernillet, L. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthritis Rheum 2005, 52(9): S102-S103.
47. Kuehl, G.E., Lampe, J.W., Potter, J.D., Bigler, J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005, 33(7): 1027-1035
48. Patel, M., Tang, B.K., Kalow, W. (S)-Oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 1995, 5(1): 43-49
49. Mukoyoshi, M., Nishimura, S., Hoshide, S., Umeda, S., Kanou, M., Taniguchi, K., Muroga, H. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: Plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008, 38(5): 496-510.
50. Burke, A., Smyth, E., Fitzgerald, G.A. Analgesic-antipyretic and antiinflammatory agents; Pharmacotherapy of gout. In: Goodman & Gillman's The Pharmacological Basis of Therapeutics, 11th Edition, L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.), http://www.accessmedicine.com/content.aspx?aID=942390, 2007.
51. Klaasen, C.D. Principles of toxicology and treatment of poisoning In: Goodman & Gillman's The Pharmacological Basis of Therapeutics, 11th Edition, L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.), http://www.accessmedicine.com/ content.aspx?aID=955752, 2007.
52. Gardiner, S.J., Begg, E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006, 58(3): 521-590
53. Hoshide, S., Takahashi, Y., Ishikawa, T. et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004, 23(8-9): 1117-1118 (Pubitemid 39625878)
54. Kamatani, N., Fujimori, S., Hada, T., Hosoya, T., Kato, R., Matsuzawa, Y., Ueda, T. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Arthritis Rheum 2003, 48(9): S530.
55. Becker, M.A., Schumacher, H., Wortmann, R.L., MacDonald, P., Palo, W., Joseph-Ridge, N. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients. Arthritis Rheum 2004, 50(9): S336.
56. Becker, M.A., Schumacher, H.R., Jr., Wortmann, R.L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353(23): 2450-2461
57. Wallace, S.L., Robinson, H., Masi, A.T., Decker, J.L., McCarty, D.J., Yu, T.F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20(3): 895-900.
58. Lawrence, M,E. Febuxostat versus allopurinol for gout. N Engl J Med 2006, 354(14): 1532.
59. Schumacher, H.R.J., Becker, M.A., Wortmann, R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59(11): 1540-1548
60. Becker, M., Schumacher, H.R., MacDonald, P.A., Lloyd, E.J., Lademacher, C., Joseph-Ridge, N. Urate-lowering therapy in subjects with gout: Interim results from the febuxostat/allopurinol comparative extension long-term study (EXCEL). Ann Rheum Dis 2007, 66(Suppl II): 230.
61. Taylor, W.J., Schumacher, H.R., Jr., Singh, J.A., Grainger, R., Dalbeth, N. Assessment of outcome in clinical trials of gout-a review of current measures. Rheumatology (Oxford) 2007, 46(12): 1751-1756 (Pubitemid 350168287)
62. odothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006, 114(23): 2508-2516 (Pubitemid 44901524)
63. Choi, H.K., Atkinson, K., Karlson, E.W., Willett, W., Curhan, G. Purine-nch foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350(11): 1093-1103 (Pubitemid 38298989)
64. Sanchez-Lozada, L.G., Tapia, E., Bautista-Garcia, P. et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008, 294(4): F710-8.
65. Sanchez-Lozada, L.G., Tapia, E., Soto, V. et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008, 108(4): 69-78. (Pubitemid 351704308)
66. Gur, M., Yilmaz, R., Demirbag, R., Aksoy, N. Relation of serum uric acid levels with the presence and severity of angiographic coronary artery disease. Angiology 2008, 59(2): 166-171
67. Wortmann, R., Becker, M.A., Schumacher, H.R., MacDonald, P., Palo, W.A., Joseph-Ridge, N. Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase Arthritis Rheum 2004, 50(9): S335.
68. Schumacher, H.R., Wortmann, R., Becker, M.A., MacDonald, P., Palo, W.A., Eustace, D., Streit J., Joseph-Ridge, N. A phase 2, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase. Arthritis Rheum 2004, 50(9): S335.
69. Schumacher, H.R. Jr., Becker, M.A., Lloyd, E., MacDonald, P.A., Lademacher, C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009, 48(2): 188-194